Science and research
We innovate pharmaceutical research and develop new medicines that enable more effective and sustainable fight against diseases.
New platinated complexes with increased antitumor activity
The project (CZ.01.01.01/01/22_002/0001041) represents synthetic and formulation research and development of new oral platinated antitumor drugs with increased antitumor activity, whose effectiveness and safety will be verified in vitro and in vivo studies. These drugs have the potential to replace existing very effective, but relatively toxic platinatum cytostatics.
The project (CZ.01.01.01/01/22_002/0001041) represents synthetic and formulation research and development of new oral platinated antitumor drugs with increased antitumor activity, whose effectiveness and safety will be verified in vitro and in vivo studies. These drugs have the potential to replace existing very effective, but relatively toxic platinatum cytostatics.
The project New platinated complexes with increased antitumor activity is co-financed by the European Union within the Operational Program Technology and Application for Competitiveness (Application, call I). The OP TAK is the controlling authority and the grant provider is the Ministry of Industry and Trade of the Czech Republic.
TU31
Clinical evaluation of phase I of the new platinated complex TU31 by oral administration, EU number 2024-511215-21-00, acronym PERPETUM. Clinical evaluation (KH) is performed by the Masaryk University Cancer Institute Brno.
Cutting-edge technologies at each stage of production
Czech quality for better health worldwide
The excellent reputation that VUAB Pharma a.s. has earned in the field of the pharmaceutical industry is based on its tradition, experience, and responsible approach to employees.
About us